Falcon Point Capital Has Cut Supernus Phamaceutical (SUPN) Holding as Stock Price Rose; Griffin Asset Management Has Lifted Its Position in Hain Celestial Group (HAIN) by $1.54 Million

May 18, 2018 - By Moses P. Lee

Falcon Point Capital Llc decreased its stake in Supernus Phamaceutical Inc (SUPN) by 5.65% based on its latest 2017Q4 regulatory filing with the SEC. Falcon Point Capital Llc sold 18,953 shares as the company’s stock rose 16.22% while stock markets declined. The institutional investor held 316,706 shares of the health care company at the end of 2017Q4, valued at $12.62 million, down from 335,659 at the end of the previous reported quarter. Falcon Point Capital Llc who had been investing in Supernus Phamaceutical Inc for a number of months, seems to be less bullish one the $2.93B market cap company. The stock decreased 3.17% or $1.85 during the last trading session, reaching $56.5. About 1.10M shares traded or 52.60% up from the average. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 46.59% since May 18, 2017 and is uptrending. It has outperformed by 35.04% the S&P500.

Griffin Asset Management Inc increased its stake in Hain Celestial Group (HAIN) by 123.47% based on its latest 2017Q4 regulatory filing with the SEC. Griffin Asset Management Inc bought 36,640 shares as the company’s stock declined 23.03% with the market. The institutional investor held 66,315 shares of the consumer non-durables company at the end of 2017Q4, valued at $2.81 million, up from 29,675 at the end of the previous reported quarter. Griffin Asset Management Inc who had been investing in Hain Celestial Group for a number of months, seems to be bullish on the $2.92 billion market cap company. The stock decreased 0.99% or $0.27 during the last trading session, reaching $26.97. About 1.33M shares traded or 0.20% up from the average. The Hain Celestial Group, Inc. (NASDAQ:HAIN) has declined 14.00% since May 18, 2017 and is downtrending. It has underperformed by 25.55% the S&P500.

More important recent The Hain Celestial Group, Inc. (NASDAQ:HAIN) news were published by: Streetinsider.com which released: “Paulson’s 13F Shows New Stake in Goldcorp (GG), Increase in Discovery (DISCA), Viacom (VIAB) (more…)” on May 15, 2018, also Seekingalpha.com published article titled: “Opko Health Shouldn’t Be Down – Cramer’s Lightning Round (5/9/18)”, Globenewswire.com published: “Market Trends Toward New Normal in Viavi Solutions, Lattice Semiconductor, Abraxas Petroleum, American Outdoor …” on May 10, 2018. More interesting news about The Hain Celestial Group, Inc. (NASDAQ:HAIN) was released by: Seekingalpha.com and their article: “Profit pressure continues at Hain Celestial” with publication date: May 08, 2018.

Griffin Asset Management Inc, which manages about $394.93M and $561.95 million US Long portfolio, decreased its stake in Caterpillar Inc. (NYSE:CAT) by 2,460 shares to 12,965 shares, valued at $2.04 million in 2017Q4, according to the filing. It also reduced its holding in Boeing (NYSE:BA) by 5,437 shares in the quarter, leaving it with 33,641 shares, and cut its stake in Abbvie Inc. (NYSE:ABBV).

Among 30 analysts covering Hain Celestial Group (NASDAQ:HAIN), 11 have Buy rating, 2 Sell and 17 Hold. Therefore 37% are positive. Hain Celestial Group had 94 analyst reports since July 24, 2015 according to SRatingsIntel. As per Thursday, February 8, the company rating was maintained by BMO Capital Markets. On Thursday, October 5 the stock rating was maintained by SunTrust with “Hold”. Wedbush maintained the stock with “Outperform” rating in Wednesday, January 13 report. The company was maintained on Thursday, September 15 by UBS. Maxim Group downgraded the shares of HAIN in report on Tuesday, August 16 to “Hold” rating. The stock of The Hain Celestial Group, Inc. (NASDAQ:HAIN) earned “Perform” rating by Oppenheimer on Tuesday, August 16. The firm earned “Sector Perform” rating on Monday, November 2 by RBC Capital Markets. The firm has “Underweight” rating by PiperJaffray given on Tuesday, August 16. As per Wednesday, December 16, the company rating was initiated by Jefferies. The stock has “Buy” rating by Maxim Group on Wednesday, January 13.

Investors sentiment increased to 1.11 in 2017 Q4. Its up 0.24, from 0.87 in 2017Q3. It is positive, as 41 investors sold HAIN shares while 91 reduced holdings. 45 funds opened positions while 101 raised stakes. 90.39 million shares or 0.62% less from 90.96 million shares in 2017Q3 were reported. State Board Of Administration Of Florida Retirement reported 0.02% in The Hain Celestial Group, Inc. (NASDAQ:HAIN). Texas Permanent School Fund has 0.04% invested in The Hain Celestial Group, Inc. (NASDAQ:HAIN). New Mexico Educational Retirement Board invested 0.04% in The Hain Celestial Group, Inc. (NASDAQ:HAIN). Panagora Asset Incorporated has invested 0% in The Hain Celestial Group, Inc. (NASDAQ:HAIN). Hgk Asset Management owns 19,727 shares or 0.12% of their US portfolio. Royal Bank & Trust Of Canada holds 0.02% of its portfolio in The Hain Celestial Group, Inc. (NASDAQ:HAIN) for 1.08M shares. Davide Leone Partners Inv Limited Liability Partnership holds 1.32% or 484,597 shares in its portfolio. Bnp Paribas Arbitrage Sa has invested 0% in The Hain Celestial Group, Inc. (NASDAQ:HAIN). Whittier Of Nevada holds 2,200 shares or 0.01% of its portfolio. Hsbc Public Ltd owns 17,580 shares. Lumina Fund Llc stated it has 123,600 shares or 0.48% of all its holdings. Peak6 Investments Lp holds 0.02% of its portfolio in The Hain Celestial Group, Inc. (NASDAQ:HAIN) for 115,046 shares. New York State Common Retirement Fund invested 0.01% in The Hain Celestial Group, Inc. (NASDAQ:HAIN). 2,000 were reported by Mercer Advisers. Woodstock Corporation holds 0.42% or 53,525 shares in its portfolio.

Since February 28, 2018, it had 1 insider buy, and 0 selling transactions for $49.02 million activity.

Investors sentiment increased to 1.1 in Q4 2017. Its up 0.12, from 0.98 in 2017Q3. It improved, as 22 investors sold SUPN shares while 93 reduced holdings. 43 funds opened positions while 83 raised stakes. 47.19 million shares or 3.19% less from 48.75 million shares in 2017Q3 were reported. Renaissance Group Inc Inc Limited Company reported 10,391 shares. Alphaone Investment Ser invested in 2.02% or 167,872 shares. Barclays Public Limited has 11,272 shares for 0% of their portfolio. Mckinley Capital Limited Liability Company Delaware reported 0.16% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Iguana Healthcare Management Limited Liability invested in 1.3% or 50,000 shares. Principal Fincl Group Inc has 409,824 shares for 0.02% of their portfolio. Schroder Invest Mgmt holds 0% or 13,624 shares. State Of Alaska Department Of Revenue holds 0.01% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 10,209 shares. Juncture Wealth Strategies Ltd holds 0.53% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 23,843 shares. Legal And General Grp Public Limited holds 0% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 101,460 shares. Oak Ridge Invests Ltd Co accumulated 0.5% or 260,676 shares. Massachusetts-based Loomis Sayles Lp has invested 0.05% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Trexquant Invest Lp holds 14,392 shares. Ashford Management invested in 4.69% or 755,612 shares. Stephens Investment Management Grp Ltd Co holds 0.17% or 183,593 shares.

Since January 2, 2018, it had 0 insider buys, and 11 selling transactions for $15.85 million activity. Another trade for 20,000 shares valued at $899,500 was sold by Bhatt Padmanabh P.. Vaughn Victor sold $1.12M worth of stock.

Among 11 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Supernus Pharmaceuticals had 39 analyst reports since August 26, 2015 according to SRatingsIntel. The company was downgraded on Tuesday, September 19 by Stifel Nicolaus. On Thursday, August 3 the stock rating was maintained by Cowen & Co with “Buy”. On Tuesday, September 5 the stock rating was maintained by Jefferies with “Buy”. Northland Capital maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) rating on Thursday, November 5. Northland Capital has “Outperform” rating and $27 target. Cantor Fitzgerald maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) rating on Wednesday, February 28. Cantor Fitzgerald has “Buy” rating and $52.0 target. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has “Buy” rating given on Monday, July 17 by Stifel Nicolaus. FBR Capital initiated the stock with “Buy” rating in Wednesday, October 18 report. Stifel Nicolaus maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Friday, September 1 with “Buy” rating. As per Monday, July 18, the company rating was downgraded by Piper Jaffray. The rating was initiated by Northland Capital with “Outperform” on Wednesday, October 28.

Another recent and important Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) news was published by Seekingalpha.com which published an article titled: “Supernus Pharmaceuticals’ (SUPN) CEO, Jack Khattar on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018.

Analysts await Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to report earnings on August, 1. They expect $0.45 EPS, up 40.63% or $0.13 from last year’s $0.32 per share. SUPN’s profit will be $23.31M for 31.39 P/E if the $0.45 EPS becomes a reality. After $0.49 actual EPS reported by Supernus Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -8.16% negative EPS growth.

The Hain Celestial Group, Inc. (NASDAQ:HAIN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Moses P. Lee

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: